ProCE Banner Activity

KEYNOTE-177: Phase III Trial of First-line Pembrolizumab vs Chemotherapy in MSI-H/dMMR Metastatic CRC

Slideset Download
Conference Coverage
Improvements in both efficacy (PFS, ORR) and safety with single-agent pembrolizumab vs standard therapy.

Released: June 04, 2020

Expiration: June 03, 2021

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie Inc.

AstraZeneca

Bayer Healthcare Pharma

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis

GlaxoSmithKline

Ipsen Biopharmaceuticals Inc

Jazz Pharmaceuticals

Karyopharm Therapeutics

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Pfizer and EMD Serono